Profile | GDS2987 / GI_39725710-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 50.2 | 70 |
GSM215244 | HMVEC_vehicle_rep2 | 33 | 60 |
GSM215253 | HMVEC_vehicle_rep3 | 36.5 | 67 |
GSM215254 | HMVEC_atorvastatin_rep1 | 10 | 27 |
GSM215282 | HMVEC_atorvastatin_rep3 | 13.4 | 31 |
GSM215344 | HMVEC_atorvastatin_rep2 | 17.5 | 40 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 14.8 | 24 |
GSM215294 | HMVEC_SLx2119_rep1 | 20.4 | 56 |
GSM215295 | HMVEC_SLx2119_rep2 | 29.8 | 51 |
GSM215296 | HMVEC_SLx2119_rep3 | 34.1 | 49 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 10.2 | 16 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 12.9 | 21 |
GSM215313 | PASMC_atorvastatin_rep3 | 2.6 | 4 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 21.8 | 35 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 0.6 | 1 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 2.4 | 4 |
GSM215327 | PASMC_SLx2119_rep1 | 28.8 | 45 |
GSM215328 | PASMC_SLx2119_rep2 | 11.9 | 22 |
GSM215329 | PASMC_SLx2119_rep3 | 16.3 | 31 |
GSM215330 | Fibroblasts_vehicle_rep1 | 84.9 | 73 |
GSM215331 | Fibroblasts_vehicle_rep2 | 53.3 | 69 |
GSM215332 | Fibroblasts_vehicle_rep3 | 93.9 | 75 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 67.7 | 72 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 82.3 | 73 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 42.4 | 64 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 71.5 | 72 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 70.1 | 72 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 65.6 | 71 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 66.6 | 72 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 65.7 | 72 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 34.6 | 61 |